Aurobindo Pharma completes acquisition of US-based Lannett Company

Listed Co AcquisitionStrategic Transactions View source PDF

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.8%1-day move

₹1538.30

prior close

₹1571.90

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.4+0.3+0.0-0.1+0.8+1.6+5.1+3.6+2.9+2.9+3.0———

Up moveDown movePending

AI summary

Aurobindo Pharma's US arm APUSA has completed the acquisition of US-based Lannett Company Inc. on June 29, 2026, after receiving US FTC approval on June 18. Lannett will operate as Lannett Company LLC, becoming a wholly owned subsidiary of APUSA. Over 400 Lannett employees will join APUSA. Integration begins immediately, focused on uninterrupted medicine supply and long-term value for stakeholders.

Likely market impact

Strengthens Aurobindo's US generics footprint with expanded product portfolio and operational scale. Positive for long-term growth.